Table 2.

Night-time sleep patterns at baseline versus catheter nights in young, healthy men and women (study III)

	Baseline nights	Catheter night	P-value
Entire sample (n = 66)
SL (1st epoch of stage 2, min)	20.3 ± 2.0	27.2 ± 2.5	0.025*
%WTASO	6.3 ± 0.5	14.0 ± 1.0	<0.001
%ST	90.0 ± 0.7	81.4 ± 1.1	<0.001
%Stage 1	4.3 ± 0.3	5.9 ± 0.4	<0.001
%Stage 2	59.7 ± 0.8	58.0 ± 0.9	NS
%SWS	13.6 ± 0.7	14.0 ± 0.8	NS
%REM	22.4 ± 0.6	22.0 ± 0.7	NS
REM latency (min)	87.6 ± 3.4	78.3 ± 3.7	0.028*
TIB	480.6 ± 0.7	478.3 ± 2.8	NS
Men (n = 32)
SL (1st epoch of stage 2, min)	17.4 ± 3.0	29.0 ± 3.9	0.005*
%WTASO	6.2 ± 0.6	16.3 ± 1.6	<0.001
%ST	90.6 ± 0.8	78.6 ± 1.4	<0.001
%Stage 1	4.4 ± 0.4	6.9 ± 0.6	<0.001
%Stage 2	60.6 ± 1.2	57.1 ± 1.5	0.003
%SWS	12.2 ± 1.1	12.6 ± 1.2	NS
%REM	22.9 ± 0.7	23.4 ± 1.0	NS
REM latency (min)	92.6 ± 5.5	77.1 ± 4.4	0.06
TIB	480.8 ± 0.2	473.0 ± 5.3	NS
Women (n = 34)
SL (1st epoch of stage 2, min)	23.1 ± 2.7	25.6 ± 3.2	NS
%WTASO	6.4 ± 0.8	11.8 ± 1.3	<0.003
%ST	89.5 ± 1.0	84.0 ± 1.5	<0.002
%Stage 1	4.2 ± 0.6	5.0 ± 0.6	<0.066
%Stage 2	58.9 ± 1.2	58.9 ± 1.2	NS
%SWS	15.0 ± 1.0	15.4 ± 1.1	NS
%REM	21.9 ± 1.0	20.8 ± 1.1	NS
REM latency (min)	82.9 ± 3.9	79.4 ± 5.9	NS
TIB	480.5 ± 1.3	483.4 ± 1.8	NS

Data represent mean ± SEM. Baseline is the average of nights 2 and 3.

SL, sleep latency; WTASO, wake time after sleep onset; ST, sleep time; SWS, slow wave sleep; REM, rapid eye movement; TIB, time in bed.

^*P-value derived from non-parametric Wilcoxon signed-ranks test.